Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France
CORSER
1 other identifier
observational
5,000
1 country
21
Brief Summary
On January 2020, the discovery of a new coronavirus (SARS-CoV-2) was officially announced by the Chinese health authorities and the World Health Organization (WHO). Its complete genome was sequenced by the laboratory of respiratory infection viruses at the Institut Pasteur on 29 January 2020 in France. This will allow the identification of antigenic structures involved in the immune response and the development of serological diagnostic tests. Many questions are being asked about this new virus and the infection it causes, including questions about the percentage of asymptomatic and pauci-symptomatic forms. Serological studies can provide answers to these questions. There is no serological test for SARS-COV-2 yet, but the laboratory of respiratory infection viruses at the Institut Pasteur is working on its development. This study proposes to carry out a collection of samples taken from subjects who travelled to China before the epidemic outbreak or suspected of being infected with SARS-CoV-2. As soon as it is available, serology will be performed on the collected samples.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2020
Typical duration for all trials
21 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 13, 2020
CompletedFirst Submitted
Initial submission to the registry
March 26, 2020
CompletedFirst Posted
Study publicly available on registry
March 27, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2023
CompletedJuly 7, 2023
July 1, 2023
3.2 years
March 26, 2020
July 6, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Presence of specific anti-SARS-CoV-2 antibodies in the different study groups.
Description of the serological status of individuals by different detection tests
One year
Secondary Outcomes (1)
Percentage of asymptomatic forms in individuals with anti-SARS-CoV-2 antibodies
One year
Study Arms (11)
CORSER-1a
Subjects who had been to China in the weeks before the outbreak began
CORSER-1b
Subject who had a clinical profile compatible with an SARS-CoV-2 infection between August 1, 2019 and February 29, 2020
CORSER-2a
Subjects with suspected CoV-2-SARS infection with negative results from RT-PCR testing of respiratory specimens
CORSER-2b
Contacts or co-exposures of confirmed CoV-2-SARS infection cases, or who have worked or stayed in a hospital where confirmed CoV-2-SARS infection has been managed
CORSER-2c
Subjects who have been exposed to a risk of infection with SARS-CoV-2 in a geographical area of SARS-CoV-2 circulation. * study among pupils, their parents and siblings, as well as teachers and non-teaching staff of a high-school located in Oise * study among pupils from 5 to 12 and their parents in elementary schools located in Oise * study among choir members
CORSER-2d
Staff of health care institutions
CORSER-2e
Subjects in care, hospitalized or residing in health care facilities
CORSER-3
Subjects returning from a humanitarian mission that started before 31/01/2020
CORSER-2f
Subjects with two symptomatic episodes of SARS-CoV-2 infection
CORSER-4
Subjects being vaccinated against COVID-19
CORSER-5
Subjects with acute SARS-CoV-2 infection and uninfected controls
Interventions
Blood samples for serological tests
Eligibility Criteria
Adults (≥ 18 years old) at the time of collection (including minors for group 2c) CORSER-1 : subjects who were in China between 08/2019 and 01/2020 and who have not been diagnosed with an SARS-CoV-2 infection; CORSER-2 : Sub-group 2a: suspected SARS-CoV-2 infection with a negative result of RT-PCR virus test on respiratory sample. Sub-group 2b: contact or co-exposure with confirmed cases of SARS-CoV-2-infection. Subgroup 2c: exposed to a risk of infection with SARS-CoV-2 in a geographic area of SARS-CoV-2 circulation. Subgroup 2d : Staff of health care institutions Subgroup 2e : hospitalized or residing in health care facilities Subgroup 2f : Subjects with two symptomatic episodes of SARS-CoV-2- infection CORSER 3 : returning from a humanitarian mission that started before the epidemic circulation of the virus in France CORSER 4 : being vaccinated against COVID-19 CORSER 5 : with acute SARS-CoV-2 infection and controls
You may qualify if:
- Affiliated with or benefiting from a Social Security system
- State of health compatible with a blood sample as defined in the protocol
You may not qualify if:
- Person benefiting from a legal protection measure or unable to express informed consent to participation
- Have had an infectious episode and/or respiratory signs in the 14 days prior to the scheduled visit (CORSER 1 and 2a, 2b)
- Have been in contact with a confirmed case of SARS-CoV-2 infection within 14 days prior to the date of the visit.(CORSER 1 and 2a, 2b)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Institut Pasteurlead
Study Sites (21)
CHU Amiens-Picardie
Amiens, France
EHPAD Villa Concorde
Asnières-sur-Seine, France
CHU François Mitterand
Dijon, France
Centre Hospitalier Départemental de Vendée
La Roche-sur-Yon, France
CHU Limoges
Limoges, France
Hôpital de la Croix Rousse
Lyon, France
EHPAD Les Etangs
Mennecy, France
CHRU de Nancy
Nancy, France
Hôpitaux de Brabois
Nancy, France
CHR Orléans
Orléans, France
Institut Mutualiste
Paris, 75014, France
Centre Médical de l'Institut Pasteur
Paris, 75015, France
Institut Pasteur
Paris, 75015, France
EHPAD Villa Lecourbe
Paris, France
Hôpital la Pitié Salpetrière
Paris, France
CHU Poitiers
Poitiers, France
Hôpital Pontchaillou
Rennes, France
CHU Saint-Etienne
Saint-Etienne, France
CHRU de Strasbourg
Strasbourg, France
CH de Tourcoing
Tourcoing, France
Hôpital Bretonneau
Tours, France
Related Publications (2)
Garcia L, Woudenberg T, Rosado J, Dyer AH, Donnadieu F, Planas D, Bruel T, Schwartz O, Prazuck T, Velay A, Fafi-Kremer S, Batten I, Reddy C, Connolly E, McElheron M, Kennelly SP, Bourke NM, White MT, Pelleau S. Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination. Viruses. 2022 Jul 8;14(7):1491. doi: 10.3390/v14071491.
PMID: 35891471DERIVEDBenetos A, Lai TP, Toupance S, Labat C, Verhulst S, Gautier S, Ungeheuer MN, Perret-Guillaume C, Levy D, Susser E, Aviv A. The Nexus Between Telomere Length and Lymphocyte Count in Seniors Hospitalized With COVID-19. J Gerontol A Biol Sci Med Sci. 2021 Jul 13;76(8):e97-e101. doi: 10.1093/gerona/glab026.
PMID: 33528568DERIVED
Biospecimen
serum, plasma, nasal swab, saliva
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Bruno HOEN, Pr
Institut Pasteur
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 26, 2020
First Posted
March 27, 2020
Study Start
March 13, 2020
Primary Completion
May 31, 2023
Study Completion
May 31, 2023
Last Updated
July 7, 2023
Record last verified: 2023-07